Methods for enhancing the immunogenicity of protein / peptide antigens by fusion to altered fcregions
By fusing protein/peptide antigens with modified antibody Fc fragments, the binding ability to Fc receptors and complement protein C1q is enhanced, solving the safety and immunogenicity problems of existing Fc fusion protein vaccines, achieving stronger humoral and cellular immune responses, and reducing the risk of side effects.
CN115461078BActive Publication Date: 2026-06-26SINO CELL TECH INC
4 Cites 0 Cited by
Patent Information
- Application Number
- CN202180029479.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-05-11
- Filing Date
- 2021-05-07
- Publication Date
- 2026-06-26
- Estimated Expiration
- 2041-05-07
AI Technical Summary
Technical Problem
Existing Fc fusion protein vaccines pose safety risks when activating the immune system, and their immunization efficacy needs improvement, especially in maintaining long-term humoral and cellular immune responses.
Method used
By fusing protein/peptide antigens with modified antibody Fc fragments, their binding ability to Fc receptors and complement protein C1q is enhanced, thereby mimicking the antigen-antibody complex to enhance the phagocytic activity of DC/B antigen-presenting cells and thus enhancing the immune effect of the antigen.
Benefits of technology
It improved the immunogenicity of the vaccine, enhanced humoral and cellular immune responses, increased antibody titers, and reduced the risk of side effects caused by overactivation of the immune system.
✦ Generated by Eureka AI based on patent content.
Abstract
A method for enhancing the immunogenicity of a protein / peptide antigen, wherein the protein / peptide antigen forms a fusion protein with an engineered antibody Fc fragment, which has an altered amino acid sequence and / or glycosylation form, and has an improved binding ability to Fc receptors and / or complement protein C1q compared with its native form. The SARS-CoV-2 vaccine prepared with the fusion protein as an immunogen has a higher binding ability to Fc receptors, can maintain long-term humoral and cellular immune responses, and the immunized animals can produce higher titers of neutralizing antibodies. The recombinant protein vaccine can be used for preventing SARS-CoV-2 infection-related diseases.
Need to check novelty before this filing date? Find Prior Art